Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Commentary|Articles|October 14, 2026
FAQ: What clinicians should know as SYD-101 heads to FDA advisory committee
Author(s)Kassi Filkins, Editor
Fact checked by: Nimesh Patel, MD
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
Advertisement
Advertisement
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee will meet October 30, 2026, to review new drug application (NDA) 219694 for SYD-101 (atropine sulfate ophthalmic solution 0.01%; Sydnexis), proposed for slowing myopia progression in children aged 3 years or older.1
Related to this article
Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.
Three experts explain why CVI can hide behind a normal eye exam and why early referral matters.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
Magdalena Stec, OD, FAAO; Noreen Shaikh, OD, FAAO; Huizi Kelly Yin, OD, FAAO; and Brenda Bohnsack, MD, PhD, detail their AAOpt 2026 session in Anaheim, California.
Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day.
Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.
Raman Bhakhri, OD, FAAO, details a session given with Denise Skiadopoulos, OD, FAAO, during the annual AAOpt meeting in Anaheim, California.
Advertisement
Advertisement